Effects of chemoradiotherapy on surface PD-L1 expression in esophageal cancer and its implications for immunotherapy
Chemotherapy, RT, and CRT can induce PD-L1 expression in various esophageal cancer cell lines. However, neoadjuvant CRT according to the CROSS protocol does not significantly induce PD-L1 <i>in vivo</i>. Considering the difference in time between pre- and post-therapeutic measurements, these findings suggest that PD-L1 upregulation due to neoadjuvant therapy may be transient <i>in vivo</i> as well. This highlights the potential benefit of administering immunotherapy in a neoadjuvant setting.
Authors
- Michael B. Ghadimi (ORCID: https://orcid.org/0000-0001-8208-1526)
- Rami A. El Shafie (ORCID: https://orcid.org/0000-0002-1355-7882)
- Hanibal Bohnenberger (ORCID: https://orcid.org/0000-0003-1038-1030)
- David Alexander Ziegler (ORCID: https://orcid.org/0000-0002-1469-8767)
- Alexander Otto König (ORCID: https://orcid.org/0000-0002-6137-9240)
- Laura Anna Fischer
- Stefan Küffer (ORCID: https://orcid.org/0000-0001-8443-601X)
- Martin Leu (ORCID: https://orcid.org/0000-0002-3883-6837)
- Leif H. Dröge (ORCID: https://orcid.org/0000-0002-5378-4246)
- Stefan Rieken (ORCID: https://orcid.org/0009-0000-7018-2856)
- Friederike Braulke
- Niklas Christian Scheele
- Lovis Hampe
- Tim Niemeier
- Anna Luisa Riedl
Institutions
- Universitätsmedizin Göttingen (DE)
- University of Göttingen (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-23
- DOI
- https://doi.org/10.3389/fimmu.2024.1509051
- Citations
- 2
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.15